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a,b,c TurkeyObjective: The objective of this study is to confirm whether there is relation between the human leucocyte antigen
(HLA) locus and restenosis after percutaneous coronary intervention (PCI) holds in our patient population and whether
it can be useful as a prognostic factor.
Methods: We examined the HLA phenotypes in 46 consecutive patients (39 men, 7 women, mean age of
57 ± 9 years) who had successful stent implantation in the coronary artery. Selective coronary arteriography was per-
formed 6 months after coronary stenting to assess the presence of restenosis. The HLA phenotyping was performed
for HLA-A,-B,-C antigens by Terasaki microlymphocytotoxicity technique and for HLA-DR alleles with PCR-SSP
technique.
Results: Restenosis(R+) was present in 12 (26.1%) patients (11 men, 1 woman, mean age of 57 ± 10 years). For HLA
Class I antigens frequency of HLA-B62 and HLA-CW2 antigen was slightly higher in restenotic patients but did not
reach statistical significance. For HLA-DR alleles restenotic patients had higher frequencies for HLA-DRB1⁄01(R+
%25, R %14.7), and HLA-DR11(R+ %41.7, R %20.6), without reaching statistical significance and lower frequen-
cies for DR7(R+ %0, R %17.6) and D13(R+%8.3, R %32.4) and HLA-DR53 (R+ %25, R %35.3) without reaching
statistical significance.
Conclusion: In conclusion, results show that there was no relationship between the development of restenosis and
HLA-subtypes.
 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.Keywords: Restenosis, HLA, Stent implantationIn light of increasing numbers of patients beingtreated with multiple percutaneous coronary
interventions (PCI), in-stent restenosis is a mount-
ing problem [1]. There are two lines of research on
the subject, the first being the development of
stents with lower incidence of restenosis, such as1016–7315  2011 King Saud University.
Production and hosting by Elsevier B.V. All rights reserved.
Peer review under responsibility of King Saud University.
URL: www.ksu.edu.sa
doi:10.1016/j.jsha.2011.10.001drug-eluting stents [2] and the second, inextrica-
bly wound up with the first is to reach an under-
standing of restenosis, its predictors and risk
factors. Identification of markers indicating a
higher risk of restenosis could be helpful in indi-
vidualizing treatment.URL: www.sha.org.sa
Table 1. Clinical characteristics of the study population.
R(+) n = 12 R() n = 34 P value
Age (years) 57 ± 9 57 ± 10 NS
Sex (male/female) 11/1 28/6 NS
Diabetes mellitus(%) 5(%) 8(%) NS
Hypertension(%) 9 (%) 27(%) NS
Smoking(%) 8(%) 23(%) NS
Total cholesterol
(mg/dl)
211 ± 29 222 ± 46 NS
Triglycerides
(mg/dl)
164 ± 81 201 ± 117 NS
HDL-cholesterol
(mg/dl)
43 ± 8 41 ± 11 NS
LDL-cholesterol
(mg/dl)
139 ± 19 144 ± 42 NS
Medications
ACEI/AT2 26% 29% NS
Calcium channel blocker 80% 83% NS
Antiaggregants 100% 100% NS
Nitrates 40% 45% NS
Statine use 100% 100% NS
Vessels disease
LAD 10 20 NS
Cx 1 6 NS
RCA 1 6 NS
Mean stenosis (%) 80.3 ± 10.8 84.7 ± 9.24 NS
R: Restenosis, NS: not significant, LAD: Left anterior descending, Cx:
Circumflex artery, RCA: Right coronary artery.
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2012;24:85–88Various factors, like inflammation [3–5], release
of cytokines and growth factors into the vessel
wall [6], intimal migration and hypertrophy of
the smooth muscle cells [7–9] are implicated in
the development of neointimal hyperplasia, the
cause of the restenotic process after stent implan-
tation. As not all patients with stent implantation
develop late restenosis, the restenotic process
may be a genetically determined immune re-
sponse. Human leukocyte antigens (HLA) are a
major histocompatibility complex and play an
important role in immune responses to human
disease. There are few studies on the putative
influence of HLA systems on the inflammatory re-
sponse after stent implantation. Watanabe et al
[10] reported a significant relation between reste-
nosis and HLA-C locus after balloon angioplasty
and indicated that HLA-type may be a prognostic
factor.
The objective of this study is to confirm whether
there is relation between the human leucocyte
antigen (HLA) locus and restenosis after percuta-
neous transluminal coronary angioplasty (PTCA)
holds in our patient population and whether it
can be useful as a prognostic factor.Material and method
Patient population and study design
We examined the HLA phenotypes in 46 consec-
utive patients (39 men, 7 women, mean age.
57 ± 9 years) who had de novo stabile, significant
coronary stenosis (>70% luminal stenosis) and
had a successful stent implantation into the coro-
nary artery. We excluded from the present study;
[1] patients who presented with acute myocardial
infarction or unstable angina, because these are
pathophysiologically characterized by plaque
instability and thrombus formation; [5] failed
PTCA patients; [3] aortocoronary artery bypass
patients, having previous stent implantation. All
were asked to undergo control angiography and
clinical follow-up at six months. The study was ap-
proved by the appropriate institutional commit-
tees, and patients gave informed consent. This
investigation conforms with the principles out-
lined in the Declaration of Helsinki.
Coronary arteriographic evaluation and stent
placement
Coronary arteriography and stent placement
were performed via the femoral artery by the stan-
dard method. Control coronary arteriography was
performed six months after coronary stenting to
assess the presence of restenosis regardless ofthe actual clinical presence or absence of ische-
mia. Among the 12 patients with restenosis 8
(66%) had clinical and noninvasive laboratory
findings of reversible ischemia. Patients’ demo-
graphic data are shown in Table 1. Coronary angi-
ograms were evaluated visually as reported in
previous studies by at least two cardiologists.
Restenosis was defined as at least 50% stenosis
on the control arteriography [1].HLA typing
All patients were typed at the Department of
Medical Biology, Istanbul Medical Faculty which
has accreditation to perform clinical HLA typing
by the European Federation of Immunogenetics.
All samples were typed at the HLA-DRB1/3/4/ loci
by the sequence-specific primer (PCR-SSP) meth-
od at low resolution [11]. This typing method is the
molecular equivalent of serological HLA-DR typ-
ing and identifies all two-digit specificities accu-
rately including the superspecificities DR52 and
DR53 encoded by the DRB3 and DRB4 genes,
respectively. PCR was performed on a 9700 ther-
mal cycle (PE Biosystems, CA).
Class I antigens were investigated using Terasa-
ki microlymphocytotoxicity assay. In serological
method, a 144-well plate containing HLA-A and
HLA-B and HLA-C antibodies were used [12].
Table 2. Number of subjects possessing each HLA-DRB1 allele
and HLA-DRB1 marker frequencies (%) in patients.
DRB1/B3/
B4/B5
Restenosis
present N = 12
Restenosis absent
N = 34
P value
DRB1⁄01 3 (25%) 5 (14.7%) 0.4
DRB1⁄03 1 (11.8%) 4 (11.8%) 1
DRB1⁄04 4 (33.3%) 9 (26.5%) 0.7
DRB1⁄07 0 (0%) 6 (17.6%) 0.3
DRB1⁄11(5)a 5 (41.7%) 7 (20.6%) 0.3
DRB1⁄12 (5)a 0 (0%) 2 (5.9%) 1
DRB1⁄13 (6)a 1(8.3%) 11 (32.4%) 0.1
DRB1⁄14 (6)a 0 (0%) 4 (11.8%) 0.5
DRB1⁄15(2)a 4 (33.3%) 3 (8.8%) 0.06
DRB1⁄16 (2)a 0 (0%) 8 (23.5%) 0.09
DRB5(51)a 3 (25%) 7 (20%) 0.7
DRB3(52)a 5 (41.7%) 16 (47.1%) 1
DRB4(53)a 3 (25%) 12 (35.3%) 1
a Numbers in brackets in the HLA-DRB1 column denote the broad
groups of DRBI specificities.
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Statistical analysis was carried out with Statisti-
cal Package for Social Sciences for Windows ver-
sion 10.0 (SPSS Inc, Chicago, USA). All non-
numeric variables are reported as frequency and
percentage, and all numeric variables are reported
as mean ± SD. The comparison of the means of
two numerical parameters was done with Stu-
dent’s t-test. Comparisons of the frequencies of
HLA subtypes and the presence and absence of
restenosis were done with v2 test. For 22 contin-
gency tables Yate’s correction was done. When
assumptions were violated for 22 contingency ta-
bles Fisher’s exact test was used. As the number of
patients were small all comparisons with p value
<0.1 were included in a logistic regression test to
check their significance. P value less than 0.05
was accepted as significant.Results
As shown in Table 1 risk factors such as age,
plasma lipid levels, blood pressure, diabetes and
smoking were not significantly different between
patients with and without restenosis. Restenosis
was present in 12 (26.1%) patients (11 man, 1 wo-
man, mean age 57 ± 10 years).
There was no significant difference between fre-
quencies of HLA-A group antigens for patients
with or without restenosis. Among the HLA-B
and HLA-C locus antigens frequency of HLA-
B62 and HLA-CW2 antigen was slightly higher
in restenosic patients but did not reach statistical
significance.
Findings for HLA-DRB1 allele and HLA-DRB1
marker frequencies (%) in patients are given on
Table 2. The frequencies of HLA-DRB⁄01(R+ %25,R %14.7, p = NS), and HLA-DRB1⁄11(R+ %41.7,
R%20.6, p = NS) were more frequent in the reste-
notic group without reaching statistical
significance.
Whereas DRB1⁄07(R+ %0, R %17.6, p = NS)
and DRB1⁄13 (R+ %8.3, R %32.4, p = NS) and
HLA-DRB4(53) (R+ %25, R %35.3, p = NS) alleles
were higher in non-restenotic patients but it also
did not reach statistical significance.Discussion
Restenosis is the most important long term
prognostic factor after coronary stent implanta-
tion. Conventional risk factors associated with
atherosclerotic processes are known to be factors
in the development of stent restenosis, however
it is also a fact that restenosis can occur in patients
in whom risk factors are rigorously controlled [1].
It is known that diabetes, multiple stents and final
minimal lumen diameter are strong predictors of
restenosis [1].
In our study there was no difference for risk fac-
tors among patients who had or did not have
restenosis. It is generally accepted that stent reste-
nosis within the first 6 months is related to vascu-
lar smooth muscle cell reactive proliferation
(neointimal hyperplasia) and increased extracellu-
lar matrix [13–15]. Stent implantation and injury
caused by the balloon triggers an inflammatory
reaction in the vessel wall. Inflammatory cells
are activated after vascular injury [5,15]. These
cells release some mediators that facilitate smooth
muscle cells migration and proliferation into the
arterial intima [7–9], cytokine and growth factor
release may result in the development of resteno-
sis [6]. The inhibition of inflammation and neoin-
timal hyperplasia in balloon injury animal
models with IL 10 (a monocyte deactivator) [16],
and blockage of b2 integrin Mac-1 activity (a leu-
cocyte adhesion molecule) either with antibodies
[17] or in Mac-1 knock out rats [18] supports the
idea that inflammation is crucial in the develop-
ment of stent restenosis. It was also reported that
nonspecific systemic stimulation of the immune
system concurrently with arterial vascular injury
facilitated neointimal formation and increased
restenosis [13].
MHC (major histocompatibility complex) mole-
cules bind peptides derived from pathogens and
self-antigens in an intracellular processing com-
partment and transport these peptides to the cell
surface for recognition by T cells. It is possible that
individual polymorphism in antigen processing
will affect its specificity, resulting in different sets
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presented to T cells in different individuals
regardless of their HLA genotype. The presence
of natural killer cells in atherosclerotic plaques
may imply that HLA gene locus may play a role
in the atherosclerotic process [19,20]. McKay et al
suggested that IgG antibodies to HLA class I anti-
gen may help predict the risk of restenosis after
PCI in their study [21]. The association of HLA-C
locus with restenosis after balloon angioplasty re-
ported by Watanabe et al may imply that HLA
antigens may have a prognostic role in the devel-
opment of restenosis. They used the serology
method for tissue typing but this method is too of-
ten hindered by a lack of discrimination due to
antibody cross reactivity or a lack of useful typing
reagents. DNA based tissue typing methods such
as PCR-SSP have been used successfully to im-
prove the quality of HLA typing [11,21]. In our
study, we used serology for HLA Class I antigens
and PCR-SSP technique for HLA-DRB, however
we found no relation between HLA antigens and
the development of restenosis or we were unable
to confirm the previous result. The results of these
studies must be interpreted with great caution as
numerous different extrinsic factors are observed
in these studies which might contribute to reste-
nosis differently. Furthermore, these studies are
of relatively small sample size and exhibit wide
confidence intervals. On the other hand, one must
take into account that it is likely that multiple fac-
tors are involved in restenosis.
In conclusion, results show that there was no
relationship between development of restenosis
and certain HLA-types suggesting that HLA typ-
ing is not a predictor for restenosis.Conflict of Interest Statement
The authors have no conflicts of interest to
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